EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Three‐Year Outcomes With a Supra‐Annular, Self‐Expanding Bioprosthesis and a Pericardial Wrap—The FORWARD PRO Study

Nicolas M Van Mieghem iD, Stephan Windecker, Ganesh Manoharan, Patrizio Lancellotti, Corrado Tamburino, Ran Kornowski iD, Holger Thiele, Haim Danenberg, Claudia Fiorina, Werner Scholtz, Stephen Brecker, Hendrik Ruge und 10 weitere

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31335 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Nicolas M Van Mieghem und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Cardiovascular Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Bioprosthesis, Aortic Valve Stenosis, Aortic Valve. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The self‐expanding, supra‐annular Evolut valve is an established platform for Transcatheter Aortic Valve Implantation (TAVI). Evolut PRO introduced an outer sealing wrap to mitigate paravalvular leakage. We evaluated the 3‐year clinical outcomes and valve performance of the Evolut PRO in standard clinical practice for severe aortic stenosis (AS) patients at intermediate or higher risk for surgery.

Methods

The FORWARD PRO prospective, single‐arm, multicentre, post‐market clinical study enrolled 638 patients with native aortic valve stenosis or failed surgical bioprosthetic aortic valve undergoing TAVI, at intermediate or high risk, with the Evolut PRO valve. Clinical and serial echocardiographic outcomes were followed‐up for 3 years.

Results

TAVI using Evolut PRO was attempted in 629 AS patients (implanted in 97%) (mean age 81.7 years; STS PROM score, 4.7%). At 3 years all‐cause mortality was 25.0%, disabling stroke 6.5% (all‐cause mortality or disabling stroke, 28.5%) and rate of new permanent pacemaker implantation 24.7%. Excellent valve haemodynamics were maintained (mean gradient 8.8 ± 4.7 mm Hg; mean effective orifice area 2.0 ± 0.5 cm 2 ) at 3 years. In a paired analysis of patients with ≥ mild paravalvular leakage (PVL) at discharge, more than two‐thirds demonstrated improved PVL at 3 years. Patients with ≥ mild PVL at discharge had higher median total calcium volume than those with no/trace PVL ( p < 0.001).

Conclusions

In clinical practice TAVI with the Evolut PRO valve is associated with favorable clinical outcomes and excellent haemodynamic performance out to 3 years. The observation of improvements in PVL over time warrants further research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve ProsthesisBioprosthesisAortic Valve StenosisAortic ValveTranscatheter Aortic Valve ReplacementPericardiumHumansMaleFemaleAged, 80 and overProsthesis DesignProspective StudiesTreatment OutcomeTime FactorsAgedRisk FactorsSeverity of Illness IndexRecovery of FunctionHemodynamics

Stichwörter der Autor:innen

aortic valve stenosisparavalvular leakpericardial wraptranscatheter aortic valve implantationtranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Department of Cardiology, Cardiovascular Institute, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Cardiology, Inselspital, Bern University Hospital, Bern, Switzerland.
  • Department of Cardiology, Regional Health Centre, Royal Victoria Hospital, Belfast, UK.
  • Cardiology Department, University Hospital of Liege, Liege, Belgium.
  • Cardiothoracic, Transplantation and Vascular Surgery Department, Azienda Policlinico-Vittorio Emanuele, Universita di Catania, Catania, Italy.
  • Cardiology Division, Rabin Medical Center, Petach Tikva, Israel.

ORCID-Profile: Nicolas M Van Mieghem, Ran Kornowski, Francesco Bedogni

Zitieren

APA

Van Mieghem, N. M., Windecker, S., Manoharan, G., Lancellotti, P., Tamburino, C., Kornowski, R., Thiele, H., Danenberg, H., Fiorina, C., Scholtz, W., Brecker, S., Ruge, H., Opdahl, A., Amoroso, G., Bedogni, F., Petronio, A. S., Nickenig, G., Harnath, A., Kempfert, J., …, & Grube, E. (2025). Three‐Year Outcomes With a Supra‐Annular, Self‐Expanding Bioprosthesis and a Pericardial Wrap—The FORWARD PRO Study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31335

Vancouver

Van Mieghem NM, Windecker S, Manoharan G, Lancellotti P, Tamburino C, Kornowski R, et al. Three‐Year Outcomes With a Supra‐Annular, Self‐Expanding Bioprosthesis and a Pericardial Wrap—The FORWARD PRO Study. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31335

BibTeX
@article{VanMieghem2025,
  author = {Van Mieghem, Nicolas M and Windecker, Stephan and Manoharan, Ganesh and Lancellotti, Patrizio and Tamburino, Corrado and Kornowski, Ran and Thiele, Holger and Danenberg, Haim and Fiorina, Claudia and Scholtz, Werner and Brecker, Stephen and Ruge, Hendrik and Opdahl, Anders and Amoroso, Giovanni and Bedogni, Francesco and Petronio, Anna Sonia and Nickenig, Georg and Harnath, Axel and Kempfert, Joerg and Oh, Jae K and Eisenberg, Ruth E and Grube, Eberhard},
  title = {Three‐Year Outcomes With a Supra‐Annular, Self‐Expanding Bioprosthesis and a Pericardial Wrap—The FORWARD PRO Study},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31335}
}
Kostenlos starten →